This article highlights ten leading cell therapy companies, all of which have promising cell therapy products being evaluated in clinical trials. These 10 companies were chosen because they are market leaders with robust financial funding, novel technologies, and strong therapeutic pipelines.
Allogeneic and Autologous Cell Therapy Companies
In this article:
- Leading Cell Therapy Companies
- Allogeneic Cell Therapy
- Allogeneic versus Autologous Cell Therapy Companies
Leading Cell Therapy Companies
- ReNeuron
- Mesoblast Ltd.
- Asterias Biotherapeutics
- TiGenix NV
- Cellectis
- Cynata Therapeutics
- Cytori Therapeutics
- Astellas Pharma, and Subsidiary Ocata Therapeutics
- Gamida Cell Ltd.
- Pluristem Therapeutics
Allogeneic Cell Therapy
As shown in the table below, allogeneic cell therapy manufacturing is much more common among leading cell therapy companies. Among the ten leading cell therapy companies analyzed below, eight focus exclusively on allogeneic cell therapy product development. One develops both autologous and allogeneic cell therapies products, and one is developing autologous cell therapies.
Table. Autologous vs. Allogeneic Product Development at Leading Cell Therapy Companies
Allogeneic versus Autologous Cell Therapy Companies
While these companies do not represent all cell therapy companies, the breakdown of autologous versus allogeneic cell therapy development among these market leaders is important to consider and reflective of broader trends across the cell therapy marketplace.
Clearly, there are opportunities for developing and manufacturing both autologous and allogeneic cell therapy products, which vary greatly in their manufacturing requirements, routes for patient administration, and cost structures. Clinical data in support of patient-specific therapy has been highly compelling.
Nonetheless, analysis of cell therapy market leaders clearly reveals that allogeneic product development is dominating over autologous product development on a global basis.
Do you think autologous or allogeneic therapies will dominate in the future? Let us know in the comments below.
Up next: Is the CAR-T Cell Therapy Craze Driving Pharma Investment into Cell Therapy Companies?